Skip to main content
Erschienen in: International Urogynecology Journal 10/2008

01.10.2008 | Original Article

Incontinence pads: recommending the best product-based wetback performance and price

verfasst von: Elisabeth A. Erekson, Sara A. Meyer, Clifford Melick, Mary T. McLennan

Erschienen in: International Urogynecology Journal | Ausgabe 10/2008

Einloggen, um Zugang zu erhalten

Abstract

Incontinence pads are available in the USA without a prescription and are commonly the first treatment option a patient with incontinence uses. The goal of this study was to examine the difference in the performance and cost of commercially available incontinence pads with the intention of providing recommendations to women. Ten different urinary incontinence products were selected. A modified wetback test was used to test product performance. For the small volume leaks, the Walgreen’s® Extra pad generally performed worse on the wetback test than the three other pads tested (p = 0.001–0.012), but four tests were not statistically significant. At larger leak volumes, the Walgreen’s® underwear generally performed worse than other products (p ≤ 0.001–0.046), with some exceptions. Brand name products generally performed better than generic products, but cost more. Undergarments and underwear do the worst job of keeping moisture inside the pad.
Literatur
1.
Zurück zum Zitat Urinary Incontinence Guideline Panel (1996) Urinary incontinence in adults: clinical practice guideline, No. 2, 1996 Update. AHCPR Publication No. 96-682. Rockville, MD, Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services. Urinary Incontinence Guideline Panel (1996) Urinary incontinence in adults: clinical practice guideline, No. 2, 1996 Update. AHCPR Publication No. 96-682. Rockville, MD, Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services.
2.
Zurück zum Zitat McClish DK, Wyman JF, Sale PG, Camp J, Earle B (1999) Use and costs of incontinence pads in female study volunteers. J Wound Ostomy Continence Nurs 26(4):207–213PubMed McClish DK, Wyman JF, Sale PG, Camp J, Earle B (1999) Use and costs of incontinence pads in female study volunteers. J Wound Ostomy Continence Nurs 26(4):207–213PubMed
3.
Zurück zum Zitat Cottenden AM, Dean GE, Brooks RJ (1997) Predicting the leakage performance of small bodyworn disposable incontinence pads using laboratory tests. Med Eng Phys 19(6):556–71PubMedCrossRef Cottenden AM, Dean GE, Brooks RJ (1997) Predicting the leakage performance of small bodyworn disposable incontinence pads using laboratory tests. Med Eng Phys 19(6):556–71PubMedCrossRef
4.
Zurück zum Zitat Cottenden AM, Rothwell JG, Leander H, Grau C, Brooks RJ (2002) An investigation of the repeatability and reproducibility of ISO 11948-1 (the Rothwell method) for measuring the absorption capacity of incontinence pads. Med Eng Phys 24:159–163PubMedCrossRef Cottenden AM, Rothwell JG, Leander H, Grau C, Brooks RJ (2002) An investigation of the repeatability and reproducibility of ISO 11948-1 (the Rothwell method) for measuring the absorption capacity of incontinence pads. Med Eng Phys 24:159–163PubMedCrossRef
5.
Zurück zum Zitat White CF (2003) Engineered structures for use in disposable incontinence products. Proc Inst Mech Eng 217(PartH):243–251 White CF (2003) Engineered structures for use in disposable incontinence products. Proc Inst Mech Eng 217(PartH):243–251
6.
Zurück zum Zitat Karlberg AT, Magnusson K (1996) Rosin components identified in diapers. Contact Dermatitis 34(3):176PubMedCrossRef Karlberg AT, Magnusson K (1996) Rosin components identified in diapers. Contact Dermatitis 34(3):176PubMedCrossRef
7.
Zurück zum Zitat Rademaker M (2004) Allergic contact dermatitis to a sanitary pad. Australas J Dermatol 45:234–235PubMedCrossRef Rademaker M (2004) Allergic contact dermatitis to a sanitary pad. Australas J Dermatol 45:234–235PubMedCrossRef
8.
Zurück zum Zitat Frantz RA, Xakellis GC Jr, Harvey PC, Lewis AR (2003) Implementing an incontinence management protocol in long-term care: clinic outcomes and cost. J Gerontol Nurs 29(8):46–53PubMed Frantz RA, Xakellis GC Jr, Harvey PC, Lewis AR (2003) Implementing an incontinence management protocol in long-term care: clinic outcomes and cost. J Gerontol Nurs 29(8):46–53PubMed
9.
Zurück zum Zitat Baker J, Norton P (1996) Evaluation of absorbent products for women with mild to moderate urinary incontinence. Appl Nurs Res 9(1):29–36PubMedCrossRef Baker J, Norton P (1996) Evaluation of absorbent products for women with mild to moderate urinary incontinence. Appl Nurs Res 9(1):29–36PubMedCrossRef
10.
Zurück zum Zitat Hellstrom L, Ekelund P, Larsson M, Milsom I (1993) Adapting incontinent patients incontinence aids to their leakage volumes. Scand J Caring Sci 7:67–71PubMed Hellstrom L, Ekelund P, Larsson M, Milsom I (1993) Adapting incontinent patients incontinence aids to their leakage volumes. Scand J Caring Sci 7:67–71PubMed
Metadaten
Titel
Incontinence pads: recommending the best product-based wetback performance and price
verfasst von
Elisabeth A. Erekson
Sara A. Meyer
Clifford Melick
Mary T. McLennan
Publikationsdatum
01.10.2008
Verlag
Springer-Verlag
Erschienen in
International Urogynecology Journal / Ausgabe 10/2008
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-008-0645-4

Weitere Artikel der Ausgabe 10/2008

International Urogynecology Journal 10/2008 Zur Ausgabe

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.